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In this position statement of the ESC Working Group on Myocardial and Pericardial Diseases an expert consensus group reviews the current
knowledge on clinical presentation, diagnosis and treatment of myocarditis, and proposes new diagnostic criteria for clinically suspected myo-
carditis and its distinct biopsy-proven pathogenetic forms. The aims are to bridge the gap between clinical and tissue-based diagnosis, to
improve management and provide a common reference point for future registries and multicentre randomised controlled trials of aetiology-
driven treatment in inflammatory heart muscle disease.
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Introduction
Myocarditis is achallengingdiagnosis due to theheterogeneityof clinical
presentations.1–3 The actual incidence of myocarditis is also difficult to
determine as endomyocardial biopsy (EMB), the diagnostic gold stand-
ard,1–3 is used infrequently.2,3 Studies addressing the issue of sudden
cardiac death in young people report a highly variable autopsy
prevalence of myocarditis, ranging from 2 to 42% of cases.4,5 Similarly,
biopsy-proven myocarditis is reported in 9–16% of adult patients with
unexplained non-ischaemic dilated cardiomyopathy (DCM)6,7 and in
46%ofchildrenwith an identifiedcauseofDCM.8 In patientspresenting
with mild symptoms and minimal ventricular dysfunction, myocarditis
often resolves spontaneously without specific treatment.9 However,
in up to 30% of cases, biopsy-proven myocarditis can progress to
† A.L.P.C. and S.P. contributed equally to the document.
* Corresponding author. Division of Cardiology,Department of Cardiological Thoracic andVascular Sciences, Padua UniversityMedical School, Policlinico Universitario, Via N Giustinani,
2, 35128 Padova, Italy. Tel: +39 (0)498212348, Fax: +39 (0)498211802, Email: alida.caforio@unipd.it
Published on behalf of the European Society of Cardiology. All rights reserved.& The Author 2013. For permissions please email: journals.permissions@oup.com
European Heart Journal (2013) 34, 2636–2648
doi:10.1093/eurheartj/eht210
 by guest on D
ecem
ber 17, 2013
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
DCMand is associated with apoor prognosis.1–3,7–9 Prognosis in myo-
carditis patients also varies according to the underlying aetiology.9 The
treatmentofmany formsofmyocarditis is symptomatic,10 but immuno-
histochemical1–3,9,10,11–15andmolecularbiologicalanalysisofEMB16as
well as autoantibody serum testing is important to identify those
patients in whom specific therapy is appropriate.9,17
In this Position Statement of the European Society of Cardiology
Working Group on Myocardial and Pericardial Diseases, an expert
consensus group has reviewed the current literature on clinical pres-
entation, diagnosis, and treatment of myocarditis and propose new
diagnostic criteria for clinically suspected myocarditis. The present
article is an opinion statement from the European Society of Cardi-
ology Working Group on Myocardial and Pericardial Diseases.
Definitions
In this document, we recommend use of existing definitions of myo-
carditis and inflammatory cardiomyopathy (Box 1), but acknowledge
that there is some confusion about the terms DCM and inflammatory
cardiomyopathy. Dilated cardiomyopathy is a clinical diagnosis based
on morphological and functional characterization of the left ventricle;
inflammatory cardiomyopathy is both a histological and functional
diagnosis characterized by myocarditis in association with systolic
and/or diastolic cardiac dysfunction; thus inflammatory cardiomyop-
athy and DCM are not mutually exclusive.
Definitions
Myocarditis (WHO /ISFC1):
Inflammatory disease of the myocardium diagnosed by established
histological*, immunological and immunohistochemical criteria**.
*N.B. established histological Dallas criteria12 defined as follows:
‘histological evidence of inflammatory infiltrates within the myocar-
dium associated with myocyte degeneration and necrosis of non-
ischaemic origin 12’.
**N.B. unspecified immunohistochemical criteria1, we propose an
abnormal inflammatory infiltrate to be defined as follows:
‘≥14 leucocytes/mm2 including up to 4 monocytes/mm2 with the
presence of CD 3 positive T-lymphocytes ≥7 cells/mm2’.15,18,19
Inflammatory Cardiomyopathy (WHO /ISFC1):
Myocarditis in association with cardiac dysfunction.
N.B. Inflammatory cardiomyopathy, involved in the pathogenesis of
DCM, includes idiopathic, autoimmune and infectious subtypes.1
Dilated Cardiomyopathy (ESC13; WHO /ISFC1):
DCM is a clinical diagnosis characterized by dilation and impaired
contraction of the left or both ventricles that is not explained by abnor-
mal loading conditions or coronary artery disease.
N.B. DCM includes idiopathic, familial/genetic, viral and/or immune,
alcoholic/toxic subtypes.1
The histological diagnosis of myocarditis includes different forms,
classified according to the type of inflammatory cell infiltrate:
lymphocytic, eosinophilic, polymorphic, giant cell myocarditis, and
cardiac sarcoidosis.2,4,12 The task groupalso recommends the follow-
ing criteria for subsets of myocarditis or inflammatory cardiomyop-
athy.1,2,9,13,14,16– 21
Viral myocarditis
Histological evidence for myocarditis associated with positive viral
polymerase chain reaction (PCR) (Table 1).
Autoimmune myocarditis
Histological myocarditis with negative viral PCR, with or without
serum cardiac autoantibodies (aabs) (Table 2).
N.B. There are autoimmune diseases (e.g. Hashimoto’s thyroiditis)
where aabs are mainly biomarkers, autoantibody-mediated forms
(e.g. Graves’ disease), in which aabs arepathogenic, andcell-mediated
autoimmune diseases, which are negative for aabs. In all cases, auto-
immune diseases are negative for infectious agents.
Viral and immune myocarditis
Histological myocarditis with positive viral PCR and positive cardiac
aabs (Table 2).
N.B. A follow-up EMB may document persistent viral myocarditis,
histological and virological resolution, or persistent virus-negative
myocarditis, with or without serum cardiac aabs, e.g. post-infectious
autoimmune disease.
Aetiology of myocarditis
Although the aetiology of myocarditis often remains undetermined, a
large variety of infectious agents, systemic diseases, drugs, and toxins
can cause the disease (Table 1).1–3,11,16,21–24 Some causes of myocardi-
tis are now largely historical or occur in very specific scenarios such as
sepsis or in immunocompromised patients. Molecular techniques,
mainly (reverse transcriptase)(RT)-PCR amplification,9,18,19,22,24–34
suggest that viral infections are the most important cause of myocarditis
in North America and Europe with genomes of enterovirus, adeno-
virus, influenza viruses, human herpes virus-6 (HHV-6),
Epstein-Barr-virus, cytomegalovirus, hepatitis C virus, and parvovirus
B19 reported in the myocardium of patients with myocarditis and
DCM. Lymphocytic and giant cell myocarditis are presumed idiopathic
or autoimmune if no viruses are identified in EMB and other known
causes are excluded (Figure 1).17 Similarly, the diagnosis of idiopathic
granulomatous myocarditis (cardiac sarcoidosis) requires negative
stains for microorganisms.2 Autoimmune myocarditis may occur with
exclusive cardiac involvement or in the context of autoimmune disor-
ders with extra-cardiac manifestations,9,11,17 most frequently in sarcoid-
osis (Figure 1), hypereosinophilic syndrome, scleroderma, and systemic
lupus erythematosus.
Pathogenesis
In human myocarditis, there is evidence for viral and autoimmune
mechanisms, acting in individuals with or without a genetic predispos-
ition (familial or sporadic cases, respectively).14,15,18,35– 103 Murine
studies of viral myocarditis23,104 – 107 are based mostly on Coxsackie-
virus B3-infected animals, which exhibit strain-specific susceptibility.
Enteroviruses that preferentially enter cardiomyocytes via specific
receptors cause severe cytopathic effects due to virus replication
in the first 2 weeks post-infection. As a consequence, a humoral
and cellular immune response, mainly consisting of macrophages
and CD4+ and CD8+ T- lymphocytes, is initiated in resistant
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animals (C57BL/6 mice, Sv129 mice) and leads to the elimination of
the infectious agent within 2 weeks following infection. In susceptible
mouse strains (e.g. A/J, ABY/SnJ, ASW/SnJ, ACA/SnJ, SWR/J, Balb/c),
viral RNA and inflammation persist in the heart for several
weeks.104 – 105 There is evidence that in these susceptible mice
strains, the ongoing infection and inflammation trigger autoimmune
reactions in the heart, most likely as a result of myocyte necrosis
and subsequent release of self-antigens previously hidden to the
immune system (Figure 2).108 The same genetically predisposed
strains of animals develop autoimmune lymphocytic or giant cell
myocarditis and later DCM after immunization with cardiac
autoantigens (e.g. cardiac myosin) or spontaneously. In common
with other autoimmune diseases such as Type 1 diabetes,
major histocompatibility complex (MHC) and non-MHC genes
appear to be responsible for the predisposition to murine
myocarditis.17,108 –115
It is likely that genetic predisposition is also important for the devel-
opment of viral116 and/or autoimmune myocarditis and its progression
to DCM in humans.35–36,117 Progression from myocarditis to DCM
seems to occur predominantly in patients with histologically confirmed
persistant (chronic) inflammation18 that cannot eliminate the infective
microbial agents32orhavedevelopedpathogeniccardiacautoantibodies
directed against myocardial structural, sarcoplasmic, or sarcolemmal
proteins. The frequency, cardiac, and disease specificity for such anti-
bodies in myocarditis/DCM are summarized in Table 2.9,36,37,118,119
Clinical presentation
Myocarditis presents in many different ways, ranging from mild symp-
toms of chest pain and palpitations associated with transient ECG
changes to life-threatening cardiogenic shock and ventricular arrhyth-
mia (Table 3). The disease may affect individuals of all ages, although it
is most frequent in the young. This diversity of clinical scenarios
implies that the diagnosis of myocarditis requires a high level of suspi-
cion early in the course of the disease and the use of appropriate inves-
tigations to identify its cause. In all cases of suspected myocarditis, it is
mandatory to exclude coronary artery disease and other cardiovascu-
lar, e.g. hypertension, or extra-cardiac non-inflammatory diseases that
could explain the clinical presentation. Rarely patients with other car-
diovascular disorders suchascoronaryartery disease, cardiomyopathy,
and hypertensive heart disease present with a clinical deterioration
caused by myocarditis that is mistakenly attributed to the natural
historyof the preexisting disease. If this is stronglysuspected by the clin-
ician, further investigation including EMB may be appropriate.
Myocarditis can be an incidental finding in autopsy studies of indi-
viduals who died of non-cardiac death or in myocardial samples
obtained for clinical reasons unrelated to the clinical suspicion of
myocarditis, for example following valve surgery or in explanted
hearts taken from patients that have received inotropic drugs. In
these circumstances, the significance of myocardial inflammation
must be interpreted cautiously in the light of the clinical scenario.
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Table 1 Causes of myocarditis/inflammatory cardiomyopathy
1. Infectious myocarditis
Bacterial Staphylococcus, Streptococcus, Pneumococcus, Meningococcus, Gonococcus, Salmonella, Corynebacterium diphtheriae, Haemophilus influenzae,
Mycobacterium (tuberculosis), Mycoplasma pneumoniae, Brucella
Spirochaetal Borrelia (Lyme disease), Leptospira (Weil disease)
Fungal Aspergillus, Actinomyces, Blastomyces, Candida, Coccidioides, Cryptococcus, Histoplasma, Mucormycoses, Nocardia, Sporothrix
Protozoal Trypanosoma cruzi, Toxoplasma gondii, Entamoeba, Leishmania
Parasitic Trichinella spiralis, Echinococcus granulosus, Taenia solium
Rickettsial Coxiella burnetii (Q fever), R. rickettsii (Rocky Mountain spotted fever), R. tsutsugamuschi
Viral RNA viruses: Coxsackieviruses A and B, echoviruses, polioviruses, influenza A and B viruses, respiratory syncytial virus, mumps virus,
measles virus, rubella virus, hepatitis C virus, dengue virus, yellow fever virus, Chikungunya virus, Junin virus, Lassa fever virus, rabies
virus, human immunodeficiency virus-1
DNA viruses: adenoviruses, parvovirus B19, cytomegalovirus, human herpes virus-6, Epstein-Barr virus, varicella-zoster virus, herpes
simplex virus, variola virus, vaccinia virus
2. Immune-mediated myocarditis
Allergens Tetanus toxoid, vaccines, serum sickness
Drugs: penicillin, cefaclor, colchicine, furosemide, isoniazid, lidocaine, tetracycline, sulfonamides, phenytoin, phenylbutazone,
methyldopa, thiazide diuretics, amitriptyline
Alloantigens Heart transplant rejection
Autoantigens Infection-negative lymphocytic, infection-negative giant cell
Associated with autoimmune or immune-oriented disorders: systemic lupus erythematosus, rheumatoid arthritis, Churg-Strauss
syndrome, Kawasaki’s disease, inflammatory bowel disease, scleroderma, polymyositis, myasthenia gravis, insulin-dependent diabetes
mellitus, thyrotoxicosis, sarcoidosis, Wegener’s granulomatosis, rheumatic heart disease (rheumatic fever)
3. Toxic myocarditis
Drugs Amphetamines, anthracyclines, cocaine, cyclophosphamide, ethanol, fluorouracil, lithium, catecholamines, hemetine, interleukin-2,
trastuzumab, clozapine
Heavy metals Copper, iron, lead (rare, more commonly cause intramyocyte accumulation)
Miscellaneous Scorpion sting, snake, and spider bites, bee and wasp stings, carbon monoxide, inhalants, phosphorus, arsenic, sodium azide
Hormones Phaeochromocytoma, vitamins: beri–beri
Physical agents Radiation, electric shock
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Diagnosis of myocarditis
Non-invasive imaging techniques such as cardiac magnetic resonance
(CMR) imaging can be useful in making the diagnosis of myocarditis
and for monitoring disease progression, but we strongly endorse the
concept that EMB should be the gold standard for the diagnosis of
definitemyocarditis.1–3 However, this implies that all patientswith sus-
pected myocarditis should undergo an EMB which is not routine prac-
tice; moreover, current guidelines recommend EMB only in a limited
number of clinical scenarios that do not include some common
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Serum cardiac autoantibodies in autoimmune myocarditis/dilated cardiomyopathy: frequency in myocarditis/
dilated cardiomyopathy, other cardiac disease (OCD) and normals
Cardiac autoantibody (Ab) % aabs positive %antibody
positive
Functional effect/clinical
relevance
References
Myoc DCM OCD Normal
Muscle-specific ASA,
(AFA,IFA,AMLA)
28–59* 9–41* NT 0–25 Myocytolysis 72,77,57,64
Cardiac-specific
AHA 41–56*,^,a 26–30*,^,a 1–4 3 Cardiac- and disease-specific early
predictors; predict DCM
development in relatives
9a,50a,35a, 36a,118a,52a
AIDA 17*,^,a 16*,^,a 2–4 0
Anti-Beta1-AR 33 40–51^ 13–55 0–13 Negative predictors, pro-apoptotic and
other in vitro effectsb
48,55,61–63,66a,72,74–76,
78,84,109,88,90,92,93,98NT 35*,^,a 16 7
73–96*,^,a 29–95*,^,a 8 0
NT 27–28 10 0
Anti-Beta2-AR NT 30–38^ 33 15 Association with idiopathic arrhythmia 53^,62,69a,89
NT 13–14
NT 30–75a 37 18
Anti-muscarinic acetylcholine
receptor-2
11 30–77c 23d–61 8–13 Negative inotropic, muscarinic effects 47d,48c,54,58,59,70,74–
75,88,94,98NT 83e Association with atrial arrhythmia
Cardiodepressant
(Fg-gamma-receptor 2a)
NT 64 Negative inotropic effects in rat and
human myocytes in vitro
56,66^,85–87,91^
Anti-Ky channel-interacting protein
2, KChIP2.6—ELISA)
NT 14^ 8 4 Increased cell death in myocytes in vitro
Anti-Alpha-MHC (cardiac-specific) 17–37*,^,a 20–46*,^,a 4–16 0–2.5 Negative predictors, pro-apoptotic 109,51a,60a, 118a,140a
Anti-Beta-MHC (muscle-cross
reactive)
68,95,96
Anti-MLC 1v NT 17^–35 25 0–15 51,67^
Anti-tropomyosin NT 55^ 21 NT 67
Anti-non-myofibrillar NT 46*,^,a 17 0 51a
Anti-MHC NT 67^ 42 NT 67
Anti-actin NT 71^ 21 NT 67
Anti-Troponin I ,T NT 1.7^–20^ 0^–18 0–4 Negative predictors 66,68,80
Anti-laminin 73 78 25–35 6 97
Anti-HSP60,70 NT 10–85^ 1–42 3 67,79
Anti-s.Na/K-ATPase 26* NT 2 Ventricular tachycardia predictors 49
Anti- ANT 91*,^,a 57*,^,a 0 0 Negative inotropic 81–83a
Anti-M7 13* 31* 10 0 65
Anti-BCKD-E2 100*^ 60*^ 4 0 46
Legend to Table 2:*P, 0.05 vs. normals; ^P, 0.05 vs. OCD.
AFA, anti-fibrillary Ab; AHA, organ-specific and partially organ-specific anti-heart aabs; AIDA, anti-intercalated disks-aabs; ANT, adenine nucleotide translocator; AMLA,
anti-myolemmal aabs; AR, adrenergic receptor; ASA, anti-sarcolemmal aabs; IFA, anti-interfibrillary aabs; BCKD, branched chain alpha-ketoacid dehydrogenase dihydrolipoyl
transacylase; HSP, heat shock protein; NT, not tested; OCD, other cardiac disease; MHC, myosin heavy chain; MLC1v, myosin light chain 1 ventricular; Myoc, myocarditis.
aCardiac and disease-specific for myocarditis/DCM.
bIncrease L-type Ca2+ current; short-term positive inotropic effects; increase in cytoplasmic cAMP, and cAMP/ FRET-activity.
c77% (in Chagas-DCM).
dIn atrial fibrillation patients.
eIn selected ELISA-positive heart failure patients.
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Figure 1 Upper panel: histopathology and immunopathology of acute lymphocytic myocarditis (first row, ×100), chronic lymphocytic myocar-
ditis (second row, ×200), sarcoidosis (third row, ×100), and giant cell myocarditis (fourth row, ×200). Left column ¼ haematoxylin-eosin (HE);
middle column ¼ staining with anti-CD3 antibody (pan T lymphocyte marker); right column ¼ staining with anti-CD68 antibody (macrophage
marker). Lower panel: short-axis (upper line) and long-axis (lower line) CMR images of a young patient with acute myocarditis. In the first two
columns, cine-SSFP images are shown in diastole and systole and suggest absence of any wall motion abnormality. In the next column, T2-weighted
edema images demonstrate the presence of patchy focal edema in the subepicardium of the inferolateral wall (red arrows). In the last column,
T1-weighted LGE images demonstrate presence of subepicardially distributed LGE (red arrows) which is typical for acute myocarditis.
A.L.P. Caforio et al.2640
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presentations of myocarditis, in particular, pseudo-infarction.120 In
order to improve recognition of myocarditis in clinical practice and
to aid selection of patients that require further diagnostic evaluation
and treatment, we propose new criteria for clinically suspected myo-
carditis for which biopsy analysis is recommended (Table 4). These cri-
teria are based upon consensus of experts and require validation in
future multicentre registries and randomized trials in patients who
have undergone EMB. Medical centres that cannot safely perform
EMB or do not have access to state-of-the-art CMR should refer
patients with clinically suspected myocarditis to a tertiary referral
unit experienced in EMB and CMR, particularly when patients
present with haemodynamic instability or life-threatening arrhythmia.
Firstline tests in patients with a clinical
presentation consistent with myocarditis
Electrocardiogram (ECG)
Electrocardiogram (ECG) is usually abnormal in myocarditis though
ECG signs are neither specific nor sensitive (Table 4).9,121,122 Some
ECG changes are more suggestive of myocarditis than others. For
example, ST-T segment elevation in myocarditis is typically concave
(rather thanconvex inmyocardial ischaemia)anddiffusewithoutrecip-
rocal changes. A-V block in the presence of mild left ventricular dilata-
tion can be due to various causes (including laminopathy), but it may
also be suggestive of Lyme disease, cardiac sarcoidosis, or giant cell
myocarditis. In recent studies, QRS prolongation was an independent
negative predictor for survival (which could be also due solely to asyn-
chrony in left bundle branch block), while Q-waves and repolarization
abnormalities were unrelated to outcome or immunohistological fea-
tures of inflammation on EMB.122
Recommendation
1. Standard 12-lead electrocardiogram should be performed in
all patients with clinically suspected myocarditis.
Echocardiography
Echocardiography helps to rule out non-inflammatory cardiac
disease such as valve disease and to monitor changes in cardiac
chamber size, wall thickness, ventricular function, and pericardial
effusions. Global ventriculardysfunction, regionalwallmotionabnor-
malities, and diastolic dysfunction with preserved ejection fraction
may occur in myocarditis.123,124 Histologically proven myocarditis
may resemble dilated, hypertrophic, and restrictive cardiomyopathy
and can mimic ischaemic heart disease.124,125 Fulminant myocarditis
often presents with a non-dilated, thickened, and hypocontractile left
ventricle as the intense inflammatory response results in interstitial
oedema and loss of ventricular contractility.123,124 The role of
newer imaging techniques such as tissue Doppler or strain-rate
imaging in the diagnosis of myocarditis remains to be determined.
Recommendations
2.Allpatientswithclinicallysuspectedmyocarditis shouldundergo
a standard trans-thoracic echocardiogram at presentation.
3. Trans-thoracic echocardiogram should be repeated during
hospitalization if there is any worsening of haemodynamics.
Figure 2 The picture shows the pathogenetic mechanisms involved in myocarditis and progression to dilated cardiomyopathy.
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Nuclear imaging
Data on radionuclide evaluation, including antimyosin antibody
imaging, are scarce but suggest that its sensitivity for detecting myo-
cardial inflammation is variable and its specificity low.125 – 128 Due to
their limited availability and risk from radiation exposure, nuclear
techniques are not routinely recommended for the diagnosis of myo-
carditis, with the possible exception of sarcoidosis.
Thallium 201 and technetium 99m scintigraphy have been used to
detect cardiac sarcoidosis but lack specificity. Gallium-67 scintig-
raphy and more recently positron emission tomography using 18
fluorodeoxyglucose are probably more sensitive and may be useful
in the acute phase of sarcoidosis and to monitor disease progres-
sion.129 – 132 The detection of extracardiac disease can suggest a diag-
nosis of cardiac sarcoidosis.
Recommendations
4. Nuclear imaging is not routinely recommended in the diag-
nosis of myocarditis, with the possible exception of sus-
pected cardiac sarcoidosis.
Cardiovascular magnetic resonance (CMR) imaging
Cardiovascular magnetic resonance imaging provides non-invasive
tissue characterization of the myocardium and can support the diag-
nosis of myocarditis (Figure 1).133 – 139 The timing of CMR in sus-
pected myocarditis will depend upon local availability and
expertise, but it is reasonable to first perform CMR in clinically
stable patients, prior to EMB. It should not be performed in life-
threatening presentations where EMB is urgently indicated.120,139
Cardiovascular magnetic resonance imaging techniques have been
evaluated in animal models of myocarditis as well as in
patients.19,20,125,133 – 139 Based on pre-clinical and clinical studies,
an ‘International Consensus Group on CMR Diagnosis of Myocar-
ditis’ published detailed recommendations on the indication, imple-
mentation, and analysis of appropriate CMR techniques for
non-invasive diagnosis of myocarditis (Lake Louise criteria).20 The
combined use of three different CMR techniques is suggested
(Table 5).134,136 – 139 One study has demonstrated good correlation
between CMR and EMB in troponin-positive patients without cor-
onary artery disease133; however, correlation is worse in patients
with a longer history of symptoms and histologically confirmed
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Table 3 Clinical presentations of patients with biopsy-proven inflammatory heart muscle disease
(1) Acute coronary syndrome-like
(a) Acute chest pain
- Frequently starting within 1–4 weeks of a respiratory or gastrointestinal infection
- Frequently associated with severe and recurrent symptoms
- In the absence of angiographic evidence of CAD
(b) ST/T wave changes
- ST-segment elevation or depression
- T-wave inversions
(c) With or without normal global or regional LV and/or RV dysfunction on echocardiography or CMR
(d) With or without increased TnT/TnI that may have a time course similar to acute myocardial infarction or a prolonged and sustained release over several
weeks or months
(2) New onset or worsening heart failure in the absence of CAD and known causes of heart failure
(a) New onset or progressive heart failure over 2 weeks to 3 months
- Dyspnoea
- Peripheral oedema
- Chest discomfort
- Fatigue
(b) Impaired systolic LVand/orRVfunction,withorwithoutan increase inwall thickness,withorwithoutdilatedLVand/orRVonechocardiographyorCMR
(c) Symptoms possibly started after a respiratory or gastrointestinal infection, or in the peri-partum period
(d) Non-specific ECG signs, bundle branch block, AV-block, and/or ventricular arrhythmias
(3) Chronic heart failure in the absence of CAD and known causes of heart failure (see point 2 above)
(a) Heart failure symptoms (with recurrent exacerbations) of .3 months duration
(b) Fatigue, palpitation, dyspnoea, atypical chest pain, arrhythmia in an ambulant patient
(c) Impaired systolic LV and/or RV function on echocardiography or CMR suggestive of DCM or non-ischaemic cardiomyopathy
(d) Non-specific ECG signs, sometimes bundle branch block and/or ventricular arrhythmias and/or AV-block
(4) ‘life-threatening condition’, in the absence of CAD and known causes of heart failure comprising
(a) Life-threatening arrhythmias and aborted sudden death
(b) Cardiogenic shock
(c) Severely impaired LV function
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chronic myocarditis and in addition CMR cannot exclude viral forms
of myocarditis.137
Recommendations
5. Cardiovascular magnetic resonance findings consistent with
myocarditis should be based onLake-Louisecriteria (Table 5).
6. Cardiovascular magnetic resonance may be considered in
clinically stable patients prior to EMB. Cardiovascular mag-
netic resonance does not replace EMB in the diagnosis of
myocarditis and should not delay EMB in life-threatening
presentations.
Biomarkers
Inflammatory markers
Erythrocyte sedimentation rate and reactive C protein levels are
often raised in myocarditis, but they do not confirm the diagnosis
and are often increased in acute pericarditis.52
Troponin and BNP levels
While cardiac troponins are more sensitive of myocyte injury in
patients with clinically suspected myocarditis than creatine kinase
levels,140,141 they are non-specific and when normal do not
exclude myocarditis.142 This also applies to cardiac hormones such
as brain natriuretic peptides,143 circulating cytokines,144 markers
related to extracellular matrix degradation,145 and new biomarkers
such as pentraxin 3, galectin 3, and growth differentiation factor 15.146
Viral antibodies
Positive viral serology does not imply myocardial infection but rather
indicates the interactionof theperipheral immunesystemwithan infec-
tious agent. Polyclonal stimulation of antibodies (IgM and IgG) may fur-
thermore lead to incorrect diagnosis. Thus, viral serology is of limited
utility in the diagnosis of viral myocarditis147 because the prevalence of
circulatory IgG antibodies to cardiotropic viruses in the general popu-
lation is high in the absence of viral heart disease.2,16,23,25,31,105 In add-
ition, infection with non-cardiotropic enteroviruses may cause an
antibody response which is indistinguishable from the response to
cardiotropic viruses2,16,23,25,31,105 and, in a recent study, there was
no correlation between virus serology and EMB findings.147 Circum-
stances in which serological testing may be helpful include suspected
hepatitis C, rickettsial phase 1 and phase 2, Lyme disease in endemic
areas, and human immunodeficiency in high-risk patients.
(b) Serum cardiac autoantibodies (aabs)
Aabs to various cardiac and muscle-specific autoantigens are
found in myocarditis and in DCM patients (Table 2).9,35,36,46–
98,109,118 Lack of viral genome on EMB with detectable serum
aabs suggests immune-mediated DCM or myocarditis.9,15,16,100
Antibodies of IgG class, which are shown to be cardiac and
disease-specific for myocarditis/ DCM, can be used as auto-
immune biomarkers for identifying at risk relatives and those
patients in whom, in the absence of active infection of the myocar-
dium, immunosuppression and/or immunomodulation may be
beneficial.9,15,16,35,36,100,118 Detection of cardiodepressant anti-
bodies in DCM also predicts haemodynamic benefits from
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Table 4 Diagnostic criteria for clinically suspected myocarditis
Clinical presentationsa
Acute chest pain, pericarditic, or pseudo-ischaemic
New-onset (days up to 3 months) or worsening of: dyspnoea at rest or exercise, and/or fatigue, with or without left and/or right heart failure signs
Subacute/chronic (.3 months) or worsening of: dyspnoea at rest or exercise, and/or fatigue, with or without left and/or right heart failure signs
Palpitation, and/or unexplained arrhythmia symptoms and/or syncope, and/or aborted sudden cardiac death
Unexplained cardiogenic shock
Diagnostic criteria
I. ECG/Holter/stress test features
Newly abnormal 12 lead ECG and/or Holter and/or stress testing, any of the following: I to III degree atrioventricular block, or bundle branch block, ST/T
wave change (ST elevation or non ST elevation, T wave inversion), sinus arrest, ventricular tachycardia or fibrillation and asystole, atrial fibrillation,
reduced R wave height, intraventricular conduction delay (widened QRS complex), abnormal Q waves, low voltage, frequent premature beats,
supraventricular tachycardia
II. Myocardiocytolysis markers
Elevated TnT/TnI
III. Functional and structural abnormalities on cardiac imaging (echo/angio/CMR)
New, otherwiseunexplainedLVand/orRVstructureand functionabnormality (including incidental finding in apparently asymptomatic subjects): regional
wall motion or global systolic or diastolic function abnormality, with or without ventricular dilatation, with or without increased wall thickness, with or
without pericardial effusion, with or without endocavitary thrombi
IV. Tissue characterization by CMR
Oedema and/or LGE of classical myocarditic pattern (see text)
Clinically suspected myocarditis if ≥1 clinical presentation and ≥1 diagnostic criteria from different categories, in the absence of: (1) angiographically detectable coronary artery
disease (coronary stenosis ≥ 50%); (2) known pre-existing cardiovascular disease or extra-cardiac causes that could explain the syndrome (e.g. valve disease, congenital heart disease,
hyperthyroidism, etc.) (see text). Suspicion is higher with higher number of fulfilled criteria.
aIf the patient is asymptomatic ≥2 diagnostic criteria should be met.
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immunoadsorption.85 Some aabs have been described to be nega-
tive predictors in myocarditis or DCM90,95 (Table 2). At present,
no commercially available cardiac autoantibody tests have been
validated against the results obtained in research laboratories; col-
laborative work among European research antibody laboratories is
in progress to overcome this difficulty.37
Recommendations
7. Troponins, erythrocyte sedimentation rate, reactive C
protein levels should be assessed in all patients.
8. Routine viral serology testing is not recommended.
9. Serum samples should be assessed, if possible, for cardiac
aabs, if one (or more) of the published tests is available
(Table 2), according to specific centre expertise. Disease-
specific aabs should preferably be tested.
Proposed criteria for clinically suspected myocarditis
In this position statement, we propose new criteria for the diagnosis
of clinically suspected myocarditis. These are based on a clinical pres-
entation consistent with the diagnosis (Table 3) and the presence of
one or more abnormalities on non-invasive testing (Table 4).
Myocarditis should be suspected in the presence of:
1 or more of the clinical presentations in Table 4, with or
without ancillary features (see below),
and
1 or more of the diagnostic criteria from different categories
(I to IV) in Table 4
or
when the patient is asymptomatic, 2 or morediagnostic criteria
from different categories (I to IV).
Ancillary features which support the clinical suspicion of myocarditis
include:
† Fever ≥38.08C at presentation or within the preceding 30 days
with or without evidence of a respiratory (chills, headache,
muscle aches, general malaise) or gastrointestinal (decreased
appetite, nausea, vomiting, diarrhoea) infection;
† peri-partum period121;
† previous clinically suspected or definite myocarditis (according to
the criteria set in Table 4);
† personal and/or family history of allergic asthma, other types of
allergy, extra-cardiac autoimmune disease, toxic agents;
† family history of DCM, myocarditis (according to the present cri-
teria).
Recommendation
10. All patients with clinically suspected myocarditis should be
considered for selective coronary angiography and EMB.
Second level investigations in clinically
suspected myocarditis
In patients fulfilling the diagnostic criteria for clinically suspected myo-
carditis, we recommend selective coronary angiography and EMB
(Figure 3). This recommendation also applies to patients with an
acute coronary syndrome-like presentation (with or without ST
segment elevation), increased cardiac troponins, preserved ventricular
systolic function with or without features suggestive of myocarditis on
CMR (Figure 1).20 At present, there are limited data on the prognostic
implications ofCMRfindings in this context, and this common scenario
was not included in a recently published AHA/ACC/HFSA scientific
statement on EMB.120 Therefore, in the absence of robust prospective
data (in suspected myocarditis with pseudo-infarct presentation and
Table 5 Diagnostic cardiac magnetic resonance criteria for myocarditis
In the setting of clinically suspected myocarditis (Tables 3–4), CMR findings are consistent with myocardial inflammation, if at least two of the following criteria
are present:
(1) Regional or global myocardial signal intensity increase in T2-weighted oedema imagesa
(2) Increased global myocardial early gadolinium enhancement ratio between myocardium and skeletal muscle in gadolinium-enhanced T1-weighted imagesb
(3) There is at least one focal lesion with non-ischaemic regional distribution in inversion recovery-prepared gadolinium-enhanced T1-weighted images (late
gadolinium enhancement)c
A CMR study is consistent with myocyte injury and/or scar caused by myocardial inflammation if Criterion 3 is present
A repeat CMR study between 1 and 2 weeks after the initial CMR study is recommended if
†None of the criteria are present, but the onset of symptoms has been very recent and there is strong clinical evidence for myocardial inflammation
†One of the criteria is present
The presence of LV dysfunction or pericardial effusion provides additional, supportive evidence for myocarditis
Table reprinted with permission from (20).
aGlobal signal intensity (SI) increase has to be quantified by an SI ratio of myocardium over skeletal muscle of≥2.0. If the edema is more subendocardial or transmural in combination
with a colocalized ischaemic (including the subendocardial layer) pattern of late gadolinium enhancement, acute myocardial infarction is more likely and should be reported.
bA global SI enhancement ratio of myocardium over skeletal muscle of ≥4.0 or an absolute myocardial enhancement of ≥45% is consistent with myocarditis.
cImages should be obtained at least 5 min after gadolinium injection; foci typically exclude the subendocardial layer, are often multifocal, and involve the subepicardium. If the late
gadolinium enhancement pattern clearly indicates myocardial infarction and is colocalized with a transmural regional edema, acute myocardial infarction is more likely and should be
reported.
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normal coronary arteries), the definitive diagnosis of myocarditis
should still be based on EMB (Figure 3).
Endomyocardial biopsy
Endomyocardial biopsy confirms the diagnosis of myocarditis and
identifies the underlying aetiology and the type of inflammation
(e.g. giant cell, eosinophilic myocarditis, sarcoidosis) which imply dif-
ferent treatments and prognosis (Figure 1).1– 3,11,14– 16 Importantly,
EMB is also the basis for safe (infection negative) immunosuppression
and antiviral treatment. If EMB is performedbyexperienced teams, its
complication rate is low (0–0.8).9,18,139,148
The recent scientific statement on EMB gave highest levels of
recommendations in the life-threatening clinical presentations.120
However, the diagnostic, prognostic, and therapeutic value of EMB
was based on the Dallas histopathologic criteria and did not
include immunohistochemistry and viral genome analysis (Figure 1).
These are established tools which should be used to achieve an aetio-
logical diagnosis.9,14– 16,18,19,22,26,30 –32,100,101,103,133,137,138
To optimize diagnostic accuracy and reduce sampling error in focal
myocarditis, EMB should be performed early in the course of the
disease and multiple specimens should be taken.2 At least three
samples, each 1–2 mm in size, should be taken (from the right or
from the left ventricle) and immediately fixed in 10% buffered formalin
at room temperature for light microscopy; additional samples should
be snap frozen in liquid nitrogen and stored at 2808C or stored in
RNA later tubes at room temperature for viral PCR.2,149 With
respect to left or right heart biopsy, some patients may clinically
present with exclusive left or right heart failure and myocarditis. In
such cases, decision for left or right heart biopsy should be made
according to the additional clinical information. To increase the diag-
nostic sensitivity of immunohistochemistry, use of a large panel of
monoclonal and polyclonal antibodies (including anti-CD3, T lympho-
cytes; anti-CD68, macrophages; and anti HLA-DR) is mandatory for
the identification and characterization of the inflammatory infiltrate
and for the detection of HLA-DR upregulation on EMB tissue sections
as marker of infectious-negative autoimmune myocarditis where im-
munosuppression may be considered.2,14,15 Other immunofluores-
cence stains used to define humoral rejection in heart transplant
EMB, such as C3d and C4d, have been recently reported as promising
markersof immune activation in patients with inflammatory cardiomy-
opathy; a limitationof these stains is that they require frozenmaterial.40
The diagnostic contribution of EMB is enhanced by molecular ana-
lysis with DNA–RNA extraction and RT-PCR amplification of viral
genome.16 In order to exclude systemic infection, peripheral blood
should be investigated in parallel with EMB2,9; quantification of virus
load and determination of virus replication may add diagnostic value.22
Suggested primer sets and PCR protocols are detailed in the sup-
plementary material online, appendix. The main technical require-
ments are as follows:
† RT-PCR detectionof viral DNAor RNA in the heart should always
be controlled by amplifying adequate positive samples containing
different viral copy numbers as well as negative controls.2 Sequen-
cing of the amplified viral gene product is mandatory in order to
identify virus subtypes and recognize contaminations.
† Blood samples should be tested by RT-PCR to detect acute sys-
temic virus infection, and to exclude persistently/latently infected
blood cells which might contaminate heart tissue samples but do
not indicate virus infection of the myocardium.2
† The detection of replicative forms of viral nucleic acids in the heart
supports apathogenic roleof virus in myocarditis; however, detec-
tion of viral mRNA by RT-PCR may be difficult to establish in EMB
due to low amounts of viral mRNA especially in longstanding
chronic myocarditis.
Recommendations
11. Tissue obtained from EMB should be analysed using hist-
ology, immunohistochemistry, and viral PCR (on heart
tissue and a blood sample).
12. At least three myocardial samples, each 1–2 mm in size,
should be taken (from the right or from the left ventricle)
and immediately fixed in 10% buffered formalin at room
temperature for light microscopy; additional samples
should be taken, snap frozen in liquid nitrogen, and stored
at 2808C, or stored in RNA later tubes at room tempera-
ture, for viral PCR.2,149
13. Endomyocardial biopsy may be repeated if necessary to
monitor response to aetiology-directed therapy, or if a
sampling error is suspected in a patient with unexplained
progression of heart failure.
Clinical management
Outcome and prognosis of myocarditis depends on aetiology, clinical
presentation, and disease stage.3,9 – 11 Acute myocarditis resolves in
about 50% of cases in the first 2–4 weeks, but about 25% will
develop persistent cardiac dysfunction and 12–25% may acutely de-
teriorate and either die or progress to end-stage DCM with a need
for heart transplantation.1– 3,6 –9,16,150 Biventricular dysfunction at
presentation has been reported as the main predictor of death or
Figure 3 The flow chart shows the proposed diagnostic ap-
proach for patients with clinically suspected myocarditis according
to Table 4.
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transplantation.1– 3,6– 9,16,150 Fulminant myocarditis is said to differ
from (sub)acute lymphocytic myocarditis in its mode of onset,
degree of haemodynamic compromise, and better outcome, but
data are relatively scarce in adult patients.150 Fulminant myocarditis
of unknown aetiology is more frequent in children and prevalent in
neonates with a dismal prognosis.10 Most studies suggest that survival
rates in giant-cell myocarditis are markedly worse.3,9,11,34,99
Molecular detection techniques for viral genome in EMB specimens
have provided conflicting prognostic information.9,18,32,151–153
Viral persistence in themyocardiumhasbeenassociatedwithventricu-
lar dysfunction and viral genome clearance with improvement of ven-
tricular function and a better 10-year prognosis.32,152 In contrast, in a
recent report, immunohistological evidence of inflammation but not
the presence of viral genome alone was an independent predictor of
survival.18 This discrepancy may relate to the variability in the viral epi-
demiology of different populations and to low numbers of events.
The frequency of specific viruses among patients who recover spon-
taneously is largelyunknown.Thismayalsoconfersomebiastothepub-
lished studies on prognosis.9,18,32,151–153 The molecular mechanisms
responsible for the reactivation of latent viral infection, the influence
of immune activation triggering viral replication in chronic myocarditis,
and immune-independent viral pathogenesis in non-inflamed hearts are
remaining gaps in the understanding of viral pathogenicity.22
(a) Conventional medical treatment
As large multicentre randomized controlled trials examining distinct
pathogenic subsets are not available,10 recommendations are based
on the consensus of the expert Task Force. The core principles of
treatment in myocarditis are optimal care of arrhythmia and of heart
failure and, where supported by evidence, aetiology-targeted therapy.
1. Haemodynamically unstable patients
Patients with haemodynamically unstable heart failure should be
managed promptly according to current ESC guidelines for heart
failure154 in intensive care units with respiratory and mechanical
cardio-pulmonary support facilities. In acute/fulminant cases with
cardiogenic shock and severe ventricular dysfunction, ventricular
assist devices or extracorporeal membrane oxygenation (ECMO)
may be needed to provide a bridge to transplant or to recov-
ery.10,155 –157 Because of its simplicity and effectiveness, ECMO
therapy can rescue this group of patients.156,157
Recommendations
14. Patients with a life-threatening presentation should be sent
to specialized units with capability for haemodynamic mon-
itoring, cardiac catheterization, and expertise in EMB.
15. In patients with haemodynamic instability, a mechanical
cardio-pulmonary assist device may be needed as a
bridge to recovery or to heart transplantation.
16. Cardiac transplantation should be deferred in the acute
phase, because recovery may occur, but can be considered
for haemodynamically unstable myocarditis patients, in-
cluding thosewith giant cellmyocarditis, if optimal pharma-
cological support and mechanical assistance cannot
stabilize the patient.
2. Haemodynamically stable patients
When myocarditis is suspected in asymptomatic or mildly symptom-
atic patients according to the criteria shown in Table 4, admission to
hospital and clinical monitoring are recommended until a definite
diagnosis is established, since the situation can evolve rapidly and a
cardiopulmonary emergency (e.g. severe heart block or life-
threatening arrhythmia) is possible and unpredictable, even if systolic
function is initially preserved.10 Exercise testing is contraindicated in
the acute stage as it can precipitate arrhythmia.
Patients with haemodynamically stable heart failure should be
treated with diuretics, angiotensin-converting enzyme inhibitor, or
angiotensin receptor blockade and beta-adrenergic blockade. In
patients who have persistent heart failure symptoms despite
optimal management, additional treatment with aldosterone antago-
nists should be considered.154 The procedure for weaning of heart
failure therapy following recovery of ventricular function is not
defined.
Non-steroidal anti-inflammatory drugs, in particular acetylsalicylic
acid, are a cornerstone of treatment for acute pericarditis, but have
been associated with increased mortality in experimental models
of myocarditis.106 – 108 Clinical data for their administration in myo-
carditis are inconclusive, and controlled trials are needed.
Recommendations
17. Management of ventricular dysfunction should be in line
with current ESC guidelines on heart failure.
3. Arrhythmia
There are no specific recommendations for the management of ar-
rhythmia in myocarditis, and so management should be in line with
current ESC guidelines. 157 –162 Sinus bradycardia, prolonged QRS
duration, increased left ventricular hypokinesisonechocardiography,
persistent or fluctuating cardiac troponin levels may precede a
life-threatening arrhythmia.10 Temporary pacing may be needed for
complete atrio-ventricular block.10 Indication for cardioverter defib-
rillator implantation (ICD) is controversial, because myocarditis may
heal completely. Bridging by a lifevest in patients with myocarditis and
severe ventricular arrhythmia (ventricular tachycardia or fibrillation)
could solve the transient problem.163
Recommendations
18. ICD implantation should be deferred until resolution of the
acute episode.
19. Arrhythmia management outside the acute phase should
be in line with current ESC guidelines on arrhythmia and
device implantation.
4. Avoidance of exercise
Physical activity should be restricted during the acute phase of myo-
carditis until the disease has completely resolved.164,165 Athletes
should be temporarily excluded from competitive and amateur-
leisure time sport activity regardless of age, gender, severity of symp-
toms, or therapeutic regimen.164,165 After resolution of the clinical
presentation (at least 6 months after the onset of the disease), clinical
A.L.P. Caforio et al.2646
 by guest on D
ecem
ber 17, 2013
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
reassessment is indicated before the athlete resumes competitive
sport.164,165 Pre-participation screening should be performed
every 6 months during the follow-up.164,165 Although the duration
of restricted physical activity in non-athletes is undefined, based
upon expert opinion of this Task Force, it seems reasonable to give
similar recommendations.
Recommendation
20. Physical activity should be restricted during the acute phase
of myocarditis and for at least 6 months in athletes and non-
athletes. This recommendation is based upon expert
opinion of this Task Force.
(b) Immunomodulatory therapy
Anti-viral therapies
There is still noapprovedantiviral-therapy for the treatmentof enter-
oviral infections. Vaccines may be an option in the future.166 Treat-
ment with acyclovir, gancyclovir, and valacyclovir may be
considered in patients with herpes virus infection,167 although their
efficacy is unproven in myocarditis. Preliminary data on interferon-
beta treatment suggest that it eliminates enteroviral and adenoviral
genomes in patients with left ventricular dysfunction,168 is associated
with improvement in NYHA functional class,169 and, specifically in
enteroviral infection, with a better 10-year prognosis.152 In general,
we recommend involvement of infectious disease specialists when
deciding on the use of specific antiviral therapies.
High dose intravenous immunoglobulin
High dose intravenous immunoglobulin (IVIG) modulates the
immune and inflammatory response by a variety of mechanisms
and is used in a number of systemic autoimmune diseases.170 Its
use has been associated with improved left ventricular ejection
fraction in chronic symptomatic heart failure of various causes,171
but IVIG was ineffective in the IMAC controlled trial of recent-onset
DCM in which only 15% of patients had biopsy-proven myocarditis
of non-specified cause.172 Nevertheless, IVIG has no major side-
effects and may be used in myocarditis refractory to conventional
heart failure therapy, both viral and autoimmune forms, particularly
if autoantibody-mediated.3 In the absence of multi-centre rando-
mized studies in biopsy-proven myocarditis/DCM of viral or auto-
immune origin, we do not give recommendations for the use of
IVIG.
Immunoadsorption (IA)
Various aabs have been detected in myocarditis and DCM patients
and for some a pathogenic role has been proposed (Table 2). Thus,
therapeutic strategies used in other auto-immune disorders,173 – 175
such as neutralization or immunoadsorption (IA) of disease-causing
aabs, might offer treatment options for autoimmune myocarditis/
DCM. Small randomized studies with DCM patients have shown
that IA induces improvement of LV function and decreases myocar-
dial inflammation76,102; a larger randomized controlled clinical trial is
currently underway in Europe. Until these results are available, we do
not give recommendations for the use of immunoadsorption.
(c) Immunosuppressive therapy
Most data on safety and efficacy of immunosuppressive regimes in
myocarditis have been obtained using steroids alone, azathioprine
and steroids, or cyclosporine A, azathioprine and steroids. Informa-
tion on other drugs is not available. Data from the few randomized
clinical trials of immunosuppression in myocarditis and DCM are
shown in Table 6. Response to therapy is reported mainly in
chronic virus-negative forms, in giant cell myocarditis, and in active
myocarditis defined as autoimmune (e.g. virus-negative and autoanti-
body positive). Conversely, immunosuppression had a neutral effect
in the Myocarditis TreatmentTrial, where patients had myocarditis of
unknown aetiology.6
It is necessary to identify possible drugs causing hypersensitivity
reactions, particularly in patients with hypereosinophilia10; the indu-
cing drug (Table 1) should not be reintroduced after recovery.10
Recently, a single-centre controlled trial suggested a beneficial
effect of combined steroid and azathioprine therapy in virus-negative
myocarditis.101 These data need to be confirmed in multicentre
studies.
Recommendations
21. Immunosuppression should be started only after ruling out
active infection on EMB by PCR.
22. Based on experience with non-cardiac autoimmune
disease, the task group recommends consideration of im-
munosuppression in proven autoimmune (e.g. infection-
negative) forms of myocarditis, with no contraindications
to immunosuppression, including giant cell myocarditis,
cardiac sarcoidosis, and myocarditis associated with
known extra-cardiac autoimmune disease.10,99
23. Steroid therapy is indicated in cardiac sarcoidosis in the
presence of ventricular dysfunction and/or arrhythmia
and in some forms of infection-negative eosinophilic or
toxic myocarditis with heart failure and/or arrhythmia.
24. Immunosuppression may be considered, on an individual
basis, in infection-negative lymphocytic myocarditis refrac-
tory to standard therapy in patients with no contraindica-
tions to immunosuppression.
25. Follow-up EMB may be required to guide the intensity and
the length of immunosuppression.
(d) Follow-up
Myocarditis patients can have partial or full clinical recovery; some
may relapse many years after the first episode. Relapses should be
managed similarly to the index episode. In patients who do not
resolve, disease may continue subclinically and lead to DCM.
The myocarditis patient with pseudo-infact presentation, normal
coronary arteries, and preserved ventricular function should be dis-
charged when cardiac enzymes have come into the normal range, and
offered long-term non-invasive cardiological follow-up. In the event
of prolonged (weeks or even months) documented increase of
cardiac enzymes, and/or progressive reduction in left and/or right
ventricular function, the patient should be readmitted to hospital
to perform EMB.
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Persistently elevated troponin T values could be due to hetero-
phile antibodies interfering with the assay. Performing a troponin I
could clarify whether persistent enzyme elevations are due to an ana-
lytic error or cardiac pathology. Similarly, chronic skeletal muscle
disease could be associated with persistently elevated low level
cardiac troponins.
Recommendations
26. All patients with myocarditis should be followed, with clin-
ical assessment, ECG, and echocardiography.
27. Long-term follow-up for patients that have experienced
myocarditis is recommended.
Summary
This position statement reviews current knowledge, and proposes
new diagnostic criteria for clinically suspected myocarditis and its dis-
tinct biopsy-proven pathogenetic forms. The aims are to bridge the
gap between clinical and tissue-based diagnosis, to improve manage-
ment and provide a common reference point for future registries and
multicentre randomized controlled trials of aetiology-driven treat-
ment in inflammatory heart muscle disease.
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